IDEC Pharmaceuticals Corporation

 

Briefing Document of 90Yttrium Ibritumomab Tiuxetan

Radioimmunotherapy Regimen

 

Erratum to page 74 (Table 48) and page 75 (Figure 17)

 

The sacral image-derived red marrow dosimetry results for 15 patients presented in Table 48 and Figure 17 are incorrect. The correct values are: 111In ibritumomab tiuxetan dose factor 0.7 cGy/mCi (range: 0.4 - 0.8 cGy/mCi), 90Y ibritumomab tiuxetan dose factor 4.7 cGy/mCi (range: 2.6 - 6.8 cGy/mCi), 90Y ibritumomab tiuxetan radiation absorbed dose 143 cGy (range: 81-190 cGy).